Nancy Miller-Rich
Director/Board Member at ALDEYRA THERAPEUTICS, INC.
Net worth: - $ as of 30/03/2024
Profile
Nancy Miller-Rich is the founder of Ten63 Therapeutics, Inc. (founded in 2020) and Miller-Rich Associates LLC (founded in 2017), where she holds the title of Chief Executive Officer.
Currently, Ms. Miller-Rich is the Chairman at BioTheryX, Inc. (since 2021), the Executive Chairman at Altum Pharmaceuticals, Inc., the Director at Global Alliance for TB Drug Development (since 2018), an Independent Director at Aldeyra Therapeutics, Inc. (since 2020), an Independent Director at 4D Molecular Therapeutics, Inc. (since 2020), a Director at Helio Vision, Inc., and an Independent Director at Attralus, Inc. Ms. Miller-Rich's former positions include being an Independent Director at Intercept Pharmaceuticals, Inc. (2018-2023), an Independent Director at Kadmon Holdings, Inc., an Independent Non-Executive Director at UDG Healthcare Ltd.
(Dublin) (2016-2020), and the SVP-Global Human Health Business Development at Merck & Co., Inc. (2013-2017).
and Schering-Plough Corp.
(1990-2017).
Ms. Miller-Rich obtained an undergraduate degree from Ithaca College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 22/05/2023 | 0 ( -.--% ) | - $ | 30/03/2024 | |
| 29/06/2023 | 0 ( -.--% ) | - $ | 30/03/2024 |
Nancy Miller-Rich active positions
| Companies | Position | Start |
|---|---|---|
| ALDEYRA THERAPEUTICS, INC. | Director/Board Member | 12/01/2020 |
| 4D MOLECULAR THERAPEUTICS, INC. | Director/Board Member | 17/11/2020 |
Global Alliance for TB Drug Development
 Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | Director/Board Member | 05/03/2018 |
Altum Pharmaceuticals, Inc.
 Altum Pharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Altum Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the clinical and commercial development of novel healthcare products for the treatment of women's gynecological neoplasia, autoimmune disorders, Hypercalcemia of Malignancy, Skeletal Related Events and Osteoporosis diseases. The company was founded in 2016 and is headquartered in Vancouver, Canada. | Chairman | - |
Attralus, Inc.
 Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | Director/Board Member | - |
| Miller-Rich Associates LLC | Chief Executive Officer | 31/12/2016 |
BioTheryX, Inc.
 BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Chairman | 22/02/2022 |
Helio Vision, Inc.
 Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | Director/Board Member | - |
Former positions of Nancy Miller-Rich
| Companies | Position | End |
|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Director/Board Member | 07/11/2023 |
| ░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░ | ░░░░░░░ | - |
Training of Nancy Miller-Rich
| Ithaca College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ALDEYRA THERAPEUTICS, INC. | Health Technology |
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| 4D MOLECULAR THERAPEUTICS, INC. | Health Technology |
| Private companies | 10 |
|---|---|
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | Health Technology |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Health Technology |
Kadmon Holdings, Inc.
 Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
UDG Healthcare Ltd. (Dublin)
 UDG Healthcare Ltd. (Dublin) Miscellaneous Commercial ServicesCommercial Services UDG Healthcare Plc engages in the supply and distribution of pharmaceutical and medical products. It operates through the following segments: Ashfield, Sharp, and Aquilant. The Ashfield segment provides commercialization services for the pharmaceutical and healthcare industry. The Sharp segment offers contract packaging and clinical trial packaging services. The Aquilant segment involves. outsourced sales, marketing, distribution, and engineering services to the medical and scientific sectors. The company was founded in 1948 and is headquartered in Dublin, Ireland. | Commercial Services |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | Health Technology |
Altum Pharmaceuticals, Inc.
Altum Pharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Altum Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the clinical and commercial development of novel healthcare products for the treatment of women's gynecological neoplasia, autoimmune disorders, Hypercalcemia of Malignancy, Skeletal Related Events and Osteoporosis diseases. The company was founded in 2016 and is headquartered in Vancouver, Canada. | Health Technology |
TEN63 Therapeutics
 TEN63 Therapeutics Pharmaceuticals: MajorHealth Technology TEN63 Therapeutics provides drug development services. The American company was founded by Nancy Miller-Rich, Marcel Frenkel, Mark Hallen, Bruce Donald. Marcel Frenkel has been the CEO since incorporation. | Health Technology |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | Health Technology |
| Miller-Rich Associates LLC |
- Stock Market
- Insiders
- Nancy Miller-Rich
